Cogent Biosciences, Inc. COGT Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Cogent Biosciences, Inc. (COGT) reported accretion (amortization) of discounts and premiums, investments of $1.18M in Q1 2026.
- How has Cogent Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Cogent Biosciences, Inc.'s accretion (amortization) of discounts and premiums, investments increased by 23.6% year-over-year, from $955K to $1.18M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- Reflects the periodic adjustment to the carrying value of investment securities to account for the difference between the purchase price and the face value at maturity. This non-cash item reconciles the interest income recognized in the income statement with the actual cash yield of the investment portfolio. It is essential for understanding the true economic return on corporate cash holdings.